Vical discontinuing HSV-2 program after Phase II miss

Vical Inc. (NASDAQ:VICL) said it will discontinue development of VCL-HB01 after the HSV-2 vaccine missed the primary endpoint in a Phase II trial.

VCL-HB01 is a plasmid DNA vaccine that encodes the HSV-2

Read the full 321 word article

User Sign In